Catalent, Inc. (NYSE:CTLT) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lowered its stake in Catalent, Inc. (NYSE:CTLT - Free Report) by 50.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,290 shares of the company's stock after selling 16,441 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Catalent were worth $732,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of CTLT. Gladius Capital Management LP bought a new position in Catalent during the third quarter worth about $28,000. Exchange Traded Concepts LLC bought a new position in shares of Catalent during the 3rd quarter worth approximately $31,000. Cary Street Partners Investment Advisory LLC raised its stake in Catalent by 1,162.3% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company's stock valued at $35,000 after acquiring an additional 709 shares during the period. Park Place Capital Corp raised its stake in Catalent by 25.2% in the 3rd quarter. Park Place Capital Corp now owns 1,533 shares of the company's stock valued at $70,000 after acquiring an additional 309 shares during the period. Finally, PFG Private Wealth Management LLC acquired a new stake in Catalent during the 3rd quarter valued at $155,000.

Catalent Price Performance

Shares of CTLT traded down $0.14 during mid-day trading on Thursday, reaching $55.81. The company had a trading volume of 1,903,179 shares, compared to its average volume of 2,541,310. The company has a market capitalization of $10.10 billion, a price-to-earnings ratio of -8.22, a P/E/G ratio of 6.04 and a beta of 1.20. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48. The company's 50 day simple moving average is $56.76 and its 200 day simple moving average is $48.53. Catalent, Inc. has a 1-year low of $31.45 and a 1-year high of $60.20.

Catalent (NYSE:CTLT - Get Free Report) last posted its earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the previous year, the firm posted $0.62 EPS. The business's quarterly revenue was down 10.2% compared to the same quarter last year. Analysts expect that Catalent, Inc. will post 0.28 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Barclays increased their target price on Catalent from $45.00 to $47.00 and gave the stock an "equal weight" rating in a research note on Thursday, January 25th. StockNews.com started coverage on shares of Catalent in a research report on Friday, April 19th. They set a "sell" rating on the stock. Stephens reiterated an "equal weight" rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th. UBS Group restated a "neutral" rating and set a $63.50 target price (up previously from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, February 20th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $52.46.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.